person · Reporting owner

Mates Sharon

Disclosed activity across 3 companies

Tapewire entity: 50018
SEC CIK: 0001585699

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Benitec Biopharma Inc.BNTC · Entity 5596	Director	January 22, 2026	January 26, 2026
Seaport Therapeutics, Inc.SPTX · Entity 4799	Director	April 30, 2026	May 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Benitec Biopharma Inc.

Report date January 22, 2026 · Filed January 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.83 · Expires 2036-01-22	Direct	31,500	Reported balance After 2026-01-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-22 · Grant · Acquired 31,500 · Balance 31,500 F1: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

Seaport Therapeutics, Inc.

Report date April 30, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29	Direct	49,033	Reported balance After 2026-04-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-30 · Grant · Acquired 49,033 · Balance 49,033 F1: 1/3rd of the shares underlying this option shall vest and become exercisable on April 30, 2027, with the remaining shares vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/3rd of the shares underlying this option shall vest and become exercisable on April 30, 2027, with the remaining shares vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Intra-Cellular Therapies, Inc.

Report date April 02, 2025 · Filed April 02, 2025

Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-04-02 transaction · row 1 1 source row Row 1 · 2025-04-02 · Disposition to issuer · Disposed 945,235 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
Common StockSEC Table I · non-derivative	IndirectBy the Sharon Mates Family Foundation	0	Reported balance After 2025-04-02 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-04-02 · Disposition to issuer · Disposed 190,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. F3: These shares are held by the Sharon Mates Family Foundation (the "Foundation"). The reporting person disclaims beneficial ownership of the shares held by the Foundation except to the extent of her pecuniary interest therein, if any.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.63 · Expires 2026-01-03	Direct	0	Reported balance After 2025-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-04-02 · Disposition to issuer · Disposed 86,003 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.73 · Expires 2027-01-02	Direct	0	Reported balance After 2025-04-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-04-02 · Disposition to issuer · Disposed 135,399 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.47 · Expires 2028-01-02	Direct	0	Reported balance After 2025-04-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-04-02 · Disposition to issuer · Disposed 138,473 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.94 · Expires 2030-02-17	Direct	0	Reported balance After 2025-04-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-04-02 · Disposition to issuer · Disposed 66,886 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.89 · Expires 2031-02-22	Direct	0	Reported balance After 2025-04-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-04-02 · Disposition to issuer · Disposed 53,471 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.73 · Expires 2032-03-09	Direct	0	Reported balance After 2025-04-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-04-02 · Disposition to issuer · Disposed 50,167 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-04-02 · Disposition to issuer · Disposed 40,713 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F8: Not applicable.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-02 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-04-02 · Disposition to issuer · Disposed 69,940 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F8: Not applicable.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-02 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-04-02 · Disposition to issuer · Disposed 121,212 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F8: Not applicable.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	40,712	Reported balance After 2025-04-02 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-04-02 · Grant · Acquired 40,712 · Balance 40,712 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F9: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration. F8: Not applicable.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-02 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-04-02 · Disposition to issuer · Disposed 40,712 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F9: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration. F8: Not applicable.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	34,970	Reported balance After 2025-04-02 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2025-04-02 · Grant · Acquired 34,970 · Balance 34,970 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F9: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration. F8: Not applicable.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-02 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2025-04-02 · Disposition to issuer · Disposed 34,970 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F9: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration. F8: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

F3: These shares are held by the Sharon Mates Family Foundation (the "Foundation"). The reporting person disclaims beneficial ownership of the shares held by the Foundation except to the extent of her pecuniary interest therein, if any.

F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.

F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable.

F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.

F8: Not applicable.

F9: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 17, 2024 Filed Jan 18, 2024 19:47 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	48,084	$0.00 Strike: $16.86	$0.00	Disclosure SEC source: 0000950170-24-005557 · ownership.xml · derivative · entry 12 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,555 Underlying: Common Stock · 48,084 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This option was granted on June 30, 2014 with an exercise price of $16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested. Read SEC document
January 17, 2024 Filed Jan 18, 2024 19:47 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	17,451	$66.66	$1,163,283.66	Disclosure SEC source: 0000950170-24-005557 · ownership.xml · nonDerivative · entry 7 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,050,309 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 to $67.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 17, 2024 Filed Jan 18, 2024 19:47 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	30,633	$66.00	$2,021,778.00	Disclosure SEC source: 0000950170-24-005557 · ownership.xml · nonDerivative · entry 6 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,067,760 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.36 to $66.3572, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 17, 2024 Filed Jan 18, 2024 19:47 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	48,084	$16.86	$810,696.24	Disclosure SEC source: 0000950170-24-005557 · ownership.xml · nonDerivative · entry 5 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,098,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2024 Filed Jan 18, 2024 19:47 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	75,361	$0.00 Strike: $16.86	$0.00	Disclosure SEC source: 0000950170-24-005557 · ownership.xml · derivative · entry 11 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,639 Underlying: Common Stock · 75,361 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This option was granted on June 30, 2014 with an exercise price of $16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested. Read SEC document
January 16, 2024 Filed Jan 18, 2024 19:47 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	5,882	$67.76	$398,564.32	Disclosure SEC source: 0000950170-24-005557 · ownership.xml · nonDerivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,050,309 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.69 to $67.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 16, 2024 Filed Jan 18, 2024 19:47 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	65,979	$67.25	$4,437,087.75	Disclosure SEC source: 0000950170-24-005557 · ownership.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,056,191 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.69 to $67.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 16, 2024 Filed Jan 18, 2024 19:47 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	3,500	$66.38	$232,330.00	Disclosure SEC source: 0000950170-24-005557 · ownership.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,122,170 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.685 to $66.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 16, 2024 Filed Jan 18, 2024 19:47 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	75,361	$16.86	$1,270,586.46	Disclosure SEC source: 0000950170-24-005557 · ownership.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,125,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 19, 2023 Filed Sep 19, 2023 20:40 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	44,413	$54.17	$2,405,852.21	Disclosure SEC source: 0001209191-23-050101 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,050,309 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.825 to $54.3884, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
September 18, 2023 Filed Sep 19, 2023 20:40 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	28,119	$53.96	$1,517,301.24	Disclosure SEC source: 0001209191-23-050101 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,094,722 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.841 to $54.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
September 18, 2023 Filed Sep 19, 2023 20:40 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	27,468	$53.55	$1,470,911.40	Disclosure SEC source: 0001209191-23-050101 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,122,841 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.85 to $53.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 13, 2023 Filed Mar 13, 2023 19:31 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $3.26	$0.00	Disclosure SEC source: 0001209191-23-018283 · doc4.xml · derivative · entry 9 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document
March 13, 2023 Filed Mar 13, 2023 19:31 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	20,000	$3.26	$65,200.00	Disclosure SEC source: 0001209191-23-018283 · doc4.xml · nonDerivative · entry 7 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 13, 2023 Filed Mar 13, 2023 19:31 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	1,412	$44.08	$62,240.96	Disclosure SEC source: 0001209191-23-018283 · doc4.xml · nonDerivative · entry 6 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,130,309 F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.82 to $44.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 13, 2023 Filed Mar 13, 2023 19:31 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	19,153	$45.06	$863,034.18	Disclosure SEC source: 0001209191-23-018283 · doc4.xml · nonDerivative · entry 5 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,131,721 F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.59 to $45.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 10, 2023 Filed Mar 13, 2023 19:31 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	20,565	$0.00	$0.00	Disclosure SEC source: 0001209191-23-018283 · doc4.xml · derivative · entry 8 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,131 Underlying: Common Stock · 20,565 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F10 · derivative.exercise_date: On March 10, 2022, the reporting person was granted 61,696 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F10 · derivative.expiration_date: On March 10, 2022, the reporting person was granted 61,696 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
March 10, 2023 Filed Mar 13, 2023 19:31 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	20,565	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-018283 · doc4.xml · nonDerivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
March 10, 2023 Filed Mar 13, 2023 19:31 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	6,805	$42.51	$289,280.55	Disclosure SEC source: 0001209191-23-018283 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,130,309 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $42.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 10, 2023 Filed Mar 13, 2023 19:31 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	34,965	$43.28	$1,513,285.20	Disclosure SEC source: 0001209191-23-018283 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137,114 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.855 to $43.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 09, 2023 Filed Mar 13, 2023 19:31 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	41,770	$0.00	$0.00	Disclosure SEC source: 0001209191-23-018283 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,172,079 F1 · kind: Represents shares issued upon the vesting of performance stock units. Read SEC document
March 06, 2023 Filed Mar 8, 2023 19:49 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantRestricted Stock Units · Derivative	122,137	$0.00	$0.00	Disclosure SEC source: 0001209191-23-017363 · doc4.xml · derivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,137 Underlying: Common Stock · 122,137 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On March 6, 2023, the reporting person was granted 122,137 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On March 6, 2023, the reporting person was granted 122,137 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 24, 2023 Filed Feb 27, 2023 19:59 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $3.26	$0.00	Disclosure SEC source: 0001209191-23-013434 · doc4.xml · derivative · entry 5 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 30,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document
February 24, 2023 Filed Feb 27, 2023 19:59 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	30,000	$3.26	$97,800.00	Disclosure SEC source: 0001209191-23-013434 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,130,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 24, 2023 Filed Feb 27, 2023 19:59 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	22,590	$47.03	$1,062,407.70	Disclosure SEC source: 0001209191-23-013434 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,309 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.875 to $47.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 23, 2023 Filed Feb 27, 2023 19:59 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	22,590	$0.00	$0.00	Disclosure SEC source: 0001209191-23-013434 · doc4.xml · derivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,590 Underlying: Common Stock · 22,590 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: On February 23, 2021, the reporting person was granted 67,769 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On February 23, 2021, the reporting person was granted 67,769 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 23, 2023 Filed Feb 27, 2023 19:59 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	22,590	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-013434 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,122,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
February 21, 2023 Filed Feb 22, 2023 20:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	251	$49.60	$12,449.60	Disclosure SEC source: 0001209191-23-011982 · doc4.xml · nonDerivative · entry 5 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,309 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. Read SEC document
February 21, 2023 Filed Feb 22, 2023 20:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	2,502	$48.70	$121,847.40	Disclosure SEC source: 0001209191-23-011982 · doc4.xml · nonDerivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,560 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $49.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 21, 2023 Filed Feb 22, 2023 20:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	2,200	$47.35	$104,170.00	Disclosure SEC source: 0001209191-23-011982 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,103,062 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.16 to $48.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 21, 2023 Filed Feb 22, 2023 20:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	22,895	$46.54	$1,065,533.30	Disclosure SEC source: 0001209191-23-011982 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,105,262 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.11 to $47.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 18, 2023 Filed Feb 22, 2023 20:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	27,848	$0.00	$0.00	Disclosure SEC source: 0001209191-23-011982 · doc4.xml · derivative · entry 6 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,848 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F7 · derivative.exercise_date: On February 18, 2020, the reporting person was granted 83,542 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On February 18, 2020, the reporting person was granted 83,542 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 18, 2023 Filed Feb 22, 2023 20:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	27,848	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-011982 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,128,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
December 13, 2022 Filed Dec 15, 2022 19:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	33,083	$55.00	$1,819,565.00	Disclosure SEC source: 0001209191-22-061532 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,309 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
March 10, 2022 Filed Mar 14, 2022 16:03 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantRestricted Stock Units · Derivative	61,696	$0.00	$0.00	Disclosure SEC source: 0001209191-22-018430 · doc4.xml · derivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,696 Underlying: Common Stock · 61,696 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On March 10, 2022, the reporting person was granted 61,696 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 10, 2022, the reporting person was granted 61,696 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
March 10, 2022 Filed Mar 14, 2022 16:03 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantStock Option (right to buy) · Derivative	50,167	$0.00 Strike: $56.73	$0.00	Disclosure SEC source: 0001209191-22-018430 · doc4.xml · derivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,167 Underlying: Common Stock · 50,167 shares Expires 2032-03-09 F1 · derivative.exercise_date: On March 10, 2022, the reporting person was granted options to purchase 50,167 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
March 09, 2022 Filed Mar 10, 2022 16:13 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	38,925	$0.00 Strike: $2.84	$0.00	Disclosure SEC source: 0001209191-22-017858 · doc4.xml · derivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,925 shares Expires 2022-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document
March 09, 2022 Filed Mar 10, 2022 16:13 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	38,925	$2.84	$110,547.00	Disclosure SEC source: 0001209191-22-017858 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,133,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 24, 2022 Filed Feb 25, 2022 19:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	100	$50.92	$5,092.00	Disclosure SEC source: 0001209191-22-013346 · doc4.xml · nonDerivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,094,467 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. Read SEC document
February 24, 2022 Filed Feb 25, 2022 19:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	11,240	$51.61	$580,096.40	Disclosure SEC source: 0001209191-22-013346 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,094,567 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 24, 2022 Filed Feb 25, 2022 19:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	11,249	$52.35	$588,885.15	Disclosure SEC source: 0001209191-22-013346 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,105,807 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.98 to $52.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 23, 2022 Filed Feb 25, 2022 19:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	22,589	$0.00	$0.00	Disclosure SEC source: 0001209191-22-013346 · doc4.xml · derivative · entry 5 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,180 Underlying: Common Stock · 22,589 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: On February 23, 2021, the reporting person was granted 67,769 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On February 23, 2021, the reporting person was granted 67,769 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 23, 2022 Filed Feb 25, 2022 19:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	22,589	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-013346 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,117,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
February 22, 2022 Filed Feb 23, 2022 19:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	12,667	$54.98	$696,431.66	Disclosure SEC source: 0001209191-22-012385 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,094,467 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.41 to $55.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 22, 2022 Filed Feb 23, 2022 19:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	15,180	$55.73	$845,981.40	Disclosure SEC source: 0001209191-22-012385 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,134 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.33 to $56.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 18, 2022 Filed Feb 23, 2022 19:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	27,847	$0.00	$0.00	Disclosure SEC source: 0001209191-22-012385 · doc4.xml · derivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,848 Underlying: Common Stock · 27,847 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: On February 18, 2020, the reporting person was granted 83,542 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On February 18, 2020, the reporting person was granted 83,542 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 18, 2022 Filed Feb 23, 2022 19:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	27,847	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-012385 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,122,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 10, 2022 Filed Jan 11, 2022 20:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	8,954	$40.10	$359,055.40	Disclosure SEC source: 0001209191-22-002984 · doc4.xml · nonDerivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,094,467 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 to $40.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 10, 2022 Filed Jan 11, 2022 20:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	27,138	$40.80	$1,107,230.40	Disclosure SEC source: 0001209191-22-002984 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,103,421 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.36 to $41.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 10, 2022 Filed Jan 11, 2022 20:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	5,804	$41.72	$242,142.88	Disclosure SEC source: 0001209191-22-002984 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,130,559 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.36 to $42.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.